Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | SVP, Strategy & Corporate Dev | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 437 |
Reported balance
After 2026-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 437 · Balance 437 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $254.34 · Expires 2036-03-01 | Direct | 1,040 |
Reported balance
After 2026-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-01 · Grant · Acquired 1,040 · Balance 1,040 F3: The stock option vests in four equal annual installments beginning on March 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
F2: The restricted stock units vest in four equal annual installments beginning on March 1, 2027.
F3: The stock option vests in four equal annual installments beginning on March 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 16:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 1,040 | $0.00 Strike: $254.34 | $0.00 |
DisclosureSEC source: 0000105770-26-000034 · form4.xml · derivative · entry 2 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,040 Underlying: Common Stock · 1,040 shares Expires 2036-03-01 F3 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 1, 2027. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 437 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000034 · form4.xml · derivative · entry 1 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437 Underlying: Common Stock · 437 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:44 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 383.382 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000025 · form4.xml · derivative · entry 3 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383.359 Underlying: Common Stock · 383.382 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 20, 2024, the reporting person was granted 1,143 restricted stock units, vesting in three equal annual installments (plus dividend equivalents). F2 · derivative.expiration_date: On February 20, 2024, the reporting person was granted 1,143 restricted stock units, vesting in three equal annual installments (plus dividend equivalents). Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:44 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 129.545 | $241.12 | $31,235.89 |
DisclosureSEC source: 0000105770-26-000025 · form4.xml · nonDerivative · entry 2 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561.235 Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:44 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 383.382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000025 · form4.xml · nonDerivative · entry 1 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690.78 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 82.299 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000020 · form4.xml · derivative · entry 3 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247.899 Underlying: Common Stock · 82.299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 18, 2025, the reporting person was granted 329 restricted stock units, vesting in four equal annual installments (plus dividend equivalents). F2 · derivative.expiration_date: On February 18, 2025, the reporting person was granted 329 restricted stock units, vesting in four equal annual installments (plus dividend equivalents). Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 27.809 | $248.26 | $6,903.86 |
DisclosureSEC source: 0000105770-26-000020 · form4.xml · nonDerivative · entry 2 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307.398 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 82.299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000020 · form4.xml · nonDerivative · entry 1 Poussot Rodolphe Jean · CIK 0002079538 · SVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335.207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.